Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Project Team Hears Report on Expert Panel Debate; Chair Voices Difficulty around Political Intervention
February 21, 2023
- LDP’s Generic League Aiming to Finalize Proposal in April for Honebuto Policy
February 21, 2023
- Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- MHLW to Launch Fact-Finding Study on COVID-19 Vaccine Reactions
February 20, 2023
- Lilly’s Ulcerative Colitis Med Up for MHLW Panel Review on March 3
February 20, 2023
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
February 16, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
- 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
- Darzquro to Escape CEA-Based Price Tweaks, Padcev Faces Cuts
February 16, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
- PM Vows Collab with Pharma for Drug Discovery; Health Minister on Relyvrio
February 16, 2023
- Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
February 15, 2023
- Label Revisions Ordered for GLP-1 Agents to Add New Side Effect Risks
February 15, 2023
- Japan Should Create Drug Discovery Command Tower: Chugai Honorary Chair
February 14, 2023
- Trade Group Calls for Predictability around SaMD Reimbursement: LDP Gathering
February 14, 2023
- J-TEC’s Cell Sheet for Vitiligo Now in Line for Approval in Japan
February 14, 2023
- Japan Extends Paxlovid Shelf Life to 24 Months
February 13, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…